A
Ajay K. Singh
Researcher at Brigham and Women's Hospital
Publications - 2123
Citations - 18370
Ajay K. Singh is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 50, co-authored 335 publications receiving 13916 citations. Previous affiliations of Ajay K. Singh include Tufts University & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
Ajay K. Singh,Lynda A. Szczech,Kezhen L. Tang,Huiman X. Barnhart,Shelly Sapp,Marsha Wolfson,Donal N. Reddan,Abstr Act +7 more
TL;DR: The use of a target hemoglobin level of 13.5 g per deciliter (as compared with 11.3 g perDeciliter) was associated with increased risk and no incremental improvement in the quality of life and the use of epoetin alfa targeted to achieve a level of 11.4 g perdeciliter was not associated with an increased risk.
Journal ArticleDOI
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer,Emmanuel A. Burdmann,Chao-Yin Chen,Mark E. Cooper,Dick de Zeeuw,Kai-Uwe Eckardt,Jan Feyzi,Peter Ivanovich,Reshma Kewalramani,Andrew S. Levey,Eldrin F. Lewis,Janet B. McGill,John J.V. McMurray,Patrick S. Parfrey,Hans-Henrik Parving,Hans-Henrik Parving,Giuseppe Remuzzi,Ajay K. Singh,Scott D. Solomon,Robert D. Toto +19 more
TL;DR: The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event ordeath or a renal event) and was associated with an increased risk of stroke.
Journal ArticleDOI
Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes
Lynda A. Szczech,Huiman X. Barnhart,Huiman X. Barnhart,Jula K. Inrig,Jula K. Inrig,Donal N. Reddan,Donal N. Reddan,Shelly Sapp,Shelly Sapp,Robert M. Califf,Uptal D. Patel,Uptal D. Patel,Ajay K. Singh +12 more
TL;DR: This study demonstrates that patients achieving their target had better outcomes than those who did not; and among subjects who achieved their randomized target, no increased risk associated with the higher hemoglobin goal was detected.
Journal ArticleDOI
Erythropoietic response and outcomes in kidney disease and type 2 diabetes
Scott D. Solomon,Hajime Uno,Eldrin F. Lewis,Kai-Uwe Eckardt,Julie Lin,Emmanuel A. Burdmann,Dick de Zeeuw,Peter Ivanovich,Andrew S. Levey,Patrick S. Parfrey,Giuseppe Remuzzi,Ajay K. Singh,Robert D. Toto,Fannie Huang,Jerome Rossert,John J.V. McMurray,Marc A. Pfeffer +16 more
TL;DR: A poor initial hematopoietic response to darbepoetin alfa was associated with an increased subsequent risk of death or cardiovascular events as doses were escalated to meet target hemoglobin levels.
Journal ArticleDOI
A Comparison of Prediction Equations for Estimating Glomerular Filtration Rate in Adults without Kidney Disease
TL;DR: The ability of the Modification of Renal Disease (MDRD) equation to predict GFR when compared with multiple other prediction equations in healthy subjects without known kidney disease was analyzed and the MDRD equations are more precise and more accurate for predicting GFR in healthy adults.